A randomised trial evaluating the effects of the TRPV1 antagonist SB705498 on pruritus induced by histamine, and cowhage challenge in healthy volunteers

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Gibson, Rachel A ^a   Robertson, Jon ^a   Mistry, Harshna ^a   McCallum, Stewart ^b   Fernando, Disala ^a   Wyres, Melody ^c   Yosipovitch, Gil ^d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c Stiefel Laboratories Inc   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; CAPSAICIN; HISTAMINE; PLACEBO; VANILLOID RECEPTOR 1; PYRROLIDINE DERIVATIVE; TRPV1 RECEPTOR; UREA; VANILLOID RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREAM; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG FORMULATION; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; EXPERIMENTAL PRURITUS; FEMALE; HISTAMINE INDUCED PRURITUS; HUMAN; MALE; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SKIN PRURITUS; VELVET BEAN; VISUAL ANALOG SCALE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; MIDDLE AGED; NORMAL HUMAN; PRURITUS; SKIN; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; CAPSAICIN; HEALTHY VOLUNTEERS; HISTAMINE; HUMANS; MALE; MIDDLE AGED; PRURITUS; PYRROLIDINES; SKIN; TRPV CATION CHANNELS; UREA;

EID: 84904698744     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100610     Document Type: Article

References (30)

1. Patel T, Yosipovitch G (2010) Therapy of Pruritus. Expert Opin Pharmacother 11:1673-1682.
2. Yosipovitch G, Goon A, Wee J (2000)The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 143: 969-973.
3. Johanek LM, Meyer RA, Hartke T, Hobelmann JG, Maine DN, et al. (2007) Psychophysical and physiological evidence for parallel afferent pathways mediating the sensation of itch. J Neurosci 27: 7490-7497. (Pubitemid 47066576)
4. Valdes-Rodriguez R, Kaushik SB, Yosipovitch G (2013) Transient receptor potential channels and dermatological disorders. Curr Top Med Chem 13: 335-343.
5. Bíró T, Tóth BI, Marincsák R, Dobrosi N, Géczy T, et al. (2007) TRP channels as novel players in the pathogenesis and therapy of itch. Biochim. Biophys. Acta - Molecular Basis of Disease 1772: 1004-1021.
6. Imamachi N, Park GH, Lee H, Anderson DJ, Simon MI, et al. (2009) TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. Proc Natl Acad Sci USA 106: 11330-11335.
7. Steinhoff S, Neisius U, Ikoma A, Fartasch M, Heyer G, et al. (2003) Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J. Neurosci 23: 6176-6180. (Pubitemid 36875617)
8. Valdes-Rodriguez R, Kaushik SB, Yosipovitch G (2013) Transient receptor potential channels and dermatological disorders. Curr Top Med Chem 13: 335-343.
9. Hutter MM, Wick EC, Day AL, Maa J, Zerega EC, et al. (2005) Transient receptor potential vanilloid (TRPV-1) promotes neurogenic inflammation in the pancreas via activation of the neurokinin-1 receptor (NK-1R). Pancreas 30: 260-265. (Pubitemid 40397379)
10. Gunthorpe MJ, Hannan S, Smart D, Jerman J, Arpino S, et al. (2007) Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-,acid-, and heat-mediated activation of the receptor. J Pharmacol Exp Ther 312: 1183-1192. (Pubitemid 46762715)
11. Chizh BA, O'Donnell MB, Napolitano A, Wang J, Brooke AC, et al. (2007) The effects of the TRPV1 antagonist on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 132: 132-141. (Pubitemid 47494566)
12. Changani K, Hotee S, Campbell S, Pindoria K, Dinnewell L, et al. (2013) Effect of the TRPV1 antagonist SB-705498 on the nasal parasympathetic reflex response in the ovalbumin sensitized guinea pig. British Journal of Pharmacology 169: 580-589.
13. Alenmyr L, Greiff L, Andersson M, Sterner O, Zygmunt PM, et al. (2012) Effect of mucosal TRPV1 inhibition in allergic rhinitis. Basic Clin Pharmacol Toxicol 110: 264-268.
14. Davis JB, Rami HK, Stevens AJ (2005) SB-705498, a clinical candidate with antagonist activity at TRPV1 and efficacy in a wide range of preclinical pain models. Presentation No. 364.2 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience. Online. Accessed 2014 Jun 5
15. Shim WS, Tak MH, Lee MH, Kim M, Kim M, et al.(2007) TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. J Neurosci 27: 2331-2337. (Pubitemid 46340952)
16. Ortonne J-P (2012) Urticaria and its subtypes: The role of second-generation antihistamines European Journal of Internal Medicine 23: 26-30.
17. Yosipovitch G, Papoiu AD (2008) What causes itch in atopic dermatitis? Curr. Allergy Asthma Rep. 8: 306-311.
18. Xiao B, Patapoutian A (2011) Scratching the surface: a role of painsensing TRPA1 in itch. Nat Neurosci 14: 540-542.
19. Reddy B (2008) Cowhage-evoked itch is mediated by a novel cysteine protease: a ligand of protease-activated receptors. J Neurosci 28: 4331-4335
20. Amadesi S, Nie J, Vergnolle N, Cottrell GS, Grady EF, et al. (2004) Protease-Activated Receptor 2 Sensitizes the Capsaicin Receptor Transient Receptor Potential Vanilloid Receptor 1 to Induce Hyperalgesia J Neurosci 24: 4300-4312.
21. Dai Y, Moriyama T, Higashi T, Togashi K, Kobayashi K, et al. (2004) Proteinase-Activated Receptor 2-Mediated Potentiation of Transient Receptor Potential Vanilloid Subfamily 1 Activity Reveals a Mechanism for Proteinase-Induced Inflammatory Pain J Neurosci 24: 4293-4299. (Pubitemid 38612819)
22. Costa R, Marotta DM, Manjavachi MN, Fernandes ES, Lima-Garcia JF, et al. (2008) Evidence for the role of neurogenic inflammation components in trypsin-elicited scratching behaviour in mice Br J Pharmacol 154: 1094-1103. (Pubitemid 351915068)
23. Belghiti M, Estévez-Herrera J, Giménez-Garzó C, González-Usano A, Montoliu C, et al. (2013) Potentiation of the transient receptor potential vanilloid 1 channel contributes to pruritogenesis in a rat model of liver disease J. Biol Chem 288: 9675-9685.
24. Yun JW, Seo JA, Jang WH, Koh HJ, Bae IH, et al. (2011) Antipruritic Effects of TRPV1 Antagonist in Murine Atopic Dermatitis and Itching Models J Invest Dermatol 131: 1576-1579.
25. Papoiu ADP, Tey HL, Coghill RC, Wang H, Yosipovitch G (2011) Cowhage-induced itch as an experimental model for pruritus. A comparative study with histamine-induced itch. PLOS ONE 6(3): e17786. doi:10.1371/journal.pone. 0017786. PubMed: 21423808.
26. Kofler L, Ulmer H, Kofler H (2011) 50-Skin-Prick Test: A Tool to Diagnose Histamine Intolerance. Scholarly Research Network ISRN Allergy. Article ID 353045, 5 pages doi:10.5402/2011/353045.
27. Francke K (2009) A study to validate a capsaicin model of experimental pain in healthy human volunteers. Clinical Pharmacology and Therapeutics 85: SUPPL. 1 (S62).
28. Lim KM, Park YH (2012) Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch Pharm Res 35: 393-396.
29. Yun JW, Seo JA, Jeong YS, Bae IH, Jang WH, et al. (2011) TRPV1 antagonist can suppress the atopic dermatitis-like symptoms by accelerating skin barrier recovery J Dermatol Sci 62: 8-15.
30. Roberson DP, Gudes S, Sprague JM, Patoski HAW, Robson VK, et al. (2013) Activity-dependent silencing reveals functionally distinct itch-generating sensory neurons Nature Neuroscience 16: 910-918.